SUBSCRIBE
SUBSCRIBE

GlaxoSmithKline Says Cervical Cancer Vaccine Works for Longer

May 14, 2008 | 
1 min read

LONDON, May 14 (Reuters) - GlaxoSmithKline said on Wednesday new data showed its Cervarix vaccine generated sustained, high levels of neutralising antibodies against the two most common cervical cancer-causing virus types for 6.4 years.

Europe
GlaxoSmithKline
MORE ON THIS TOPIC
Novo Nordisk advertising flags and logo on facade
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
December 12, 2024
 · 
1 min read
 · 
Kate Goodwin
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
A handshake of businessmen. Modern design with a positive context. Concept of help, support, and agreement between businessmen. Modern art collage, trendy magazine style.
Mergers & acquisitions
Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust Scrutiny Mounts
December 9, 2024
 · 
2 min read
 · 
Tristan Manalac
Facade of Novo Nordisk's office in Fremont, California
Manufacturing
Novo Continues Manufacturing Spending Spree With $400M Denmark Expansion, $200M Plant Purchase
December 5, 2024
 · 
2 min read
 · 
Tristan Manalac